- Home
- SILC vs ADVM Comparison
SILC vs ADVM Comparison
Compare SILC & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILC
- ADVM
- Stock Information
- Founded
- SILC 1987
- ADVM 2006
- Country
- SILC Israel
- ADVM United States
- Employees
- SILC N/A
- ADVM N/A
- Industry
- SILC Computer Manufacturing
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILC Technology
- ADVM Health Care
- Exchange
- SILC Nasdaq
- ADVM Nasdaq
- Market Cap
- SILC 91.4M
- ADVM 98.0M
- IPO Year
- SILC 1994
- ADVM 2014
- Fundamental
- Price
- SILC $14.90
- ADVM $4.45
- Analyst Decision
- SILC Hold
- ADVM Strong Buy
- Analyst Count
- SILC 2
- ADVM 6
- Target Price
- SILC N/A
- ADVM $27.83
- AVG Volume (30 Days)
- SILC 26.2K
- ADVM 136.1K
- Earning Date
- SILC 05-01-2025
- ADVM 05-08-2025
- Dividend Yield
- SILC N/A
- ADVM N/A
- EPS Growth
- SILC N/A
- ADVM N/A
- EPS
- SILC N/A
- ADVM N/A
- Revenue
- SILC $58,114,000.00
- ADVM $1,000,000.00
- Revenue This Year
- SILC $6.22
- ADVM N/A
- Revenue Next Year
- SILC $19.10
- ADVM $1,162.55
- P/E Ratio
- SILC N/A
- ADVM N/A
- Revenue Growth
- SILC N/A
- ADVM N/A
- 52 Week Low
- SILC $11.35
- ADVM $3.52
- 52 Week High
- SILC $18.24
- ADVM $14.21
- Technical
- Relative Strength Index (RSI)
- SILC 39.78
- ADVM 45.50
- Support Level
- SILC $14.38
- ADVM $4.76
- Resistance Level
- SILC $15.37
- ADVM $5.23
- Average True Range (ATR)
- SILC 0.68
- ADVM 0.48
- MACD
- SILC 0.04
- ADVM -0.05
- Stochastic Oscillator
- SILC 17.87
- ADVM 20.52
About SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters; Edge Networking Solutions; FPGA Based Cards; x86 Open Appliances Bypass Switches and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.